ClinicalTrials.gg
CompletedNCT03770039Updated Mar 6, 2019

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

A Phase 1 interventional study of Oral PF-06700841 containing 14C microtracer and Oral unlabeled PF-06700841 in Healthy Male Subjects, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • PF-06700841
  • mass balance
  • metabolites
  • absolute bioavailability
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Exclusion Criteria:

  • Any malabsorption condition (eg, gastrectomy, bowel resection).
  • Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
  • History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
  • Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
  • Use of herbal supplements within 28 days prior to the first dose of study medication
  • Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
  • Inability to have at least one bowel movement every 2 days on average of \<90 mL/mim/1.73 m2 based on MDRD equation
  • Have been vaccinated with live or attenuated within the 6 weeks prior to the first dose of product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    2-period, fixed sequence

    fixed sequence with 2 treatment period

    Drug: Oral PF-06700841 containing 14C microtracer · Drug: Oral unlabeled PF-06700841 · Drug: IV 14C-labeled PF-06700841

Interventions

  • DrugOral PF-06700841 containing 14C microtracer

    Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period

  • DrugOral unlabeled PF-06700841

    60 mg unlabeled PF-06700841 oral dose in 2nd period

  • DrugIV 14C-labeled PF-06700841

    30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

06

What researchers measure

Primary outcomes

  1. mass balance_urine

    cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered

    Time frame: hour 0 up to 312 hours post dose

  2. mass balance_feces

    cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered

    Time frame: hour 0 up to 312 hours post dose

Secondary outcomes

  1. metabolite identification_plasma

    metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  2. plasma Cmax for total 14C radioactivity

    maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  3. plasma Tmax for total 14C radioactivity

    time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  4. plasma AUClast for total 14C radioactivity

    area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  5. plasma AUCinf for total 14C radioactivity

    area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  6. Oral clearance for total 14C radioactivity

    oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  7. plasma half-life for total 14C radioactivity

    half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  8. volume of distribution for total 14C radioactivity

    apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  9. plasma Cmax for PF-06700841

    maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  10. plasma Tmax for PF-06700841

    time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  11. plasma AUClast for PF-06700841

    area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  12. plasma AUCinf for PF-06700841

    area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  13. Oral clearance for PF-06700841

    oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  14. plasma half-life for PF-06700841

    half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  15. volume of distribution for PF-06700841

    apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  16. plasma Cmax for 14C-labeled PF-06700841

    maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  17. plasma Tmax for 14C-labeled PF-06700841

    time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  18. plasma AUClast for 14C-labeled PF-06700841

    area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  19. plasma AUCinf for 14C-labeled PF-06700841

    area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  20. clearance for 14C-labeled PF-06700841

    clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  21. plasma half-life for 14C-labeled PF-06700841

    half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  22. volume of distribution for 14C-labeled PF-06700841

    volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  23. unchanged PF-06700841 recovered in urine

    percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  24. renal clearance of PF-06700841

    renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841)

    Time frame: hour 0 up to 96 hours post dose

  25. Bioavailability of oral PF-06700841

    Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841

    Time frame: hour 0 up to 96 hours post dose

  26. Fraction absorbed of oral PF-06700841

    Fraction absorbed in gut (Fa) following oral dose of PF-06700841

    Time frame: hour 0 up to 144 hours post dose

  27. metabolite identification_urine

    metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

  28. metabolite identification_feces

    metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841

    Time frame: hour 0 up to 312 hours post dose

07

Study locations

2 sites
  • PRA Health Sciences
    Groningen, 9728 NZ, Netherlands
  • PRA Health Sciences Utrecht
    Utrecht, 3584 BL, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Feb 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 10, 2018
StartActual
Dec 10, 2018
Primary completionActual
Feb 21, 2019
CompletionActual
Feb 21, 2019
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03770039
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 10, 2018
Start date
Dec 10, 2018
Primary completion
Feb 21, 2019
Completion
Feb 21, 2019
Last update
Mar 6, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion